Context Therapeutics Inc. CNTX
Context Therapeutics Inc. (Nasdaq: CNTX) is an oncology drug developer. Its lead program, CTIM-76, is in Phase 1 for CLDN6-positive gynecologic and testicular cancers; platinum-resistant ovarian cancer. Its next catalyst on record is CTIM-76: Initiation of Phase 1b dose expansion trial (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: CTIM-76 — Initiation of Phase 1b dose expansion trial (Q1 2027). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| CTIM-76 (CLDN6 x CD3 T cell engager) | platinum-resistant ovarian cancer; gynecologic and testicular cancers | antibody | Phase 1 |
| CT-202 (Nectin-4 x CD3 T cell engager) | Nectin-4-positive urothelial, colorectal, triple-negative breast cancers | antibody | Phase 1 |
| CT-95 (MSLN x CD3 T cell engager) | mesothelin-expressing solid tumors (internal development discontinued Aug 2026; Phase 1 being wound down) | antibody | Phase 1 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.